$PTCHF

PureTech Health (PRTC) will present Phase 1b data for LYT-200 in R/R HR-MDS and AML at ESMO 2026, indicating potential advancement to Phase 2 trials. The company believes the data supports further development, aligning with its strategy of progressing assets from founded entities.

Panmure Liberum initiated coverage of PureTech Health with a 'buy' rating and 200p target, citing undervaluation and potential shareholder cash returns. The broker estimates $220M in June 2026 cash, funding operations until 2028, with Seaport Therapeutics stake exceeding market value. Near-term cash release may come from partial Seaport sale, but timing is uncertain. PureTech's strategy shift reduces costs but relies on external funding.

PureTech Health reported H1 earnings, highlighting a $17.5M contribution to Celea and $70M reserved for potential future investment. The company expects annual cash burn of $30M-$40M. PureTech generated over $1B from Cobenfy rights and estimates $50M in future proceeds. Gallop Oncology, a PureTech subsidiary, seeks funding for a Phase II MDS study with FDA Fast Track designation. PureTech aims to complete financing by H1 2025.

PureTech Health (PRTC) announced FDA Fast Track designation for LYT-200, an experimental therapy for relapsed/refractory high-risk myelodysplastic syndromes. The FDA feedback supports advancing LYT-200 into Phase 2 trials. The therapy, developed by Gallop Oncology, targets galectin-9 and will be evaluated in a Phase 2 study with 125 patients. PRTC shares closed at $16.00, down 3.03%.

PureTech announced positive topline data from its Phase 1b trial of LYT-200 for relapsed/refractory high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML), showing complete responses and favorable tolerability. The company plans to prioritize R/R HR-MDS for further development and engage with the FDA for a potential registration-supporting trial. LYT-200, an anti-galectin-9 monoclonal antibody, demonstrated robust antileukemic activity, including a 45.5% overall response rate in HR-MDS patients.

PureTech Health PLC (NASDAQ:PRTC) stock dropped in premarket trading after the company received FDA feedback supporting advancement for its idiopathic pulmonary fibrosis (IPF) drug, deupirfenidone, into a pivotal Phase 3 trial. Despite the positive regulatory path, investor concern arose over the timeline, as the Phase 3 trial is not expected to start until the first half of 2026. The new trial aims for potential registration via a 505(b)(2) pathway, building on promising Phase 2b results.

PureTech Health has launched Celea Therapeutics, a new biotech company focused on developing a respiratory disease treatment. Celea Therapeutics will advance deupirfenidone (LYT-100), an improved version of pirfenidone, for idiopathic pulmonary fibrosis and other inflammatory lung diseases. The drug has shown positive results in a Phase 2b trial and is moving toward Phase 3 discussions with the FDA.

PureTech Health (PRTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Image source: The Motley Fool.Thursday, August 28, 2025, at 9 a.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...

PureTech Health ( NASDAQ:PRTC ) reported its second quarter 2025 earnings on Aug. 28, 2025, highlighting a cash balance of just under $320 million at the end of the first half of 2025, a reduction in consolidated operating expenses to $50 million from $66.7 million year-over-year in the first ...